Transforming Type 2 Diabetes Management
Azurity Pharmaceuticals, Inc. has recently made a significant advancement in diabetes care with the introduction of BRYNOVIN™ (sitagliptin), an oral solution formulated specifically for adults managing type 2 diabetes mellitus. This unique liquid form is designed to help those who face challenges with traditional pill formats, allowing greater adherence to treatment and ultimately better health outcomes.
BRYNOVIN: A New Option for Patients
BRYNOVIN is a dipeptidyl peptidase-4 (DPP-4) inhibitor that assists in enhancing glycemic control. It stands out as the first and only oral liquid sitagliptin, filling a crucial gap in the market where patients often struggle with swallowing tablets. This new formulation opens doors for individuals who may have difficulties due to age or conditions that impair swallowing.
A Commitment to Patient-Centric Care
Ron Scarboro, CEO of Azurity Pharmaceuticals, highlighted the company’s dedication to reshaping diabetes management. He stated, "BRYNOVIN demonstrates our commitment to breaking down barriers to patient care. Our goal is to provide options for adult patients with T2DM that may have difficulty swallowing pills or fear of needles." This philosophy drives their continual innovation in dosage forms, striving to serve patients more effectively.
Addressing the Needs of a Large Patient Population
In the United States alone, over 38 million individuals live with diabetes, with 90-95% diagnosed with type 2 diabetes. This staggering statistic underscores the immense demand for varied treatment options, particularly for older adults and those in long-term care facilities. For these patients, the experience of taking medication can be fraught with difficulty.
Dosage and Administration of BRYNOVIN
For optimal management of type 2 diabetes, BRYNOVIN is recommended to be taken once daily at a dose of 100 mg (25 mg/mL), which equates to 4 mL. It is intended to be used in conjunction with diet and exercise, whether alone or in combination with other antihyperglycemic medications. However, it is crucial to note that BRYNOVIN is not suitable for patients with type 1 diabetes, nor has it been evaluated in those with a history of pancreatitis.
About Azurity Pharmaceuticals
Founded with the commitment to serve overlooked patients, Azurity Pharmaceuticals operates globally in over 50 countries. The company focuses on delivering high-quality, innovative medicines across multiple therapeutic areas. With a diversified portfolio including over 50 medicines and a commitment to leveraging cutting-edge technology, Azurity exemplifies a modern approach to pharmaceutical care. Their Next-Gen Commercial Model utilizes data, analytics, and AI to optimize market engagement and reach.
Frequently Asked Questions
What is BRYNOVIN and its primary use?
BRYNOVIN is an oral liquid solution of sitagliptin, primarily used to manage glycemic control in adults with type 2 diabetes mellitus.
Who is eligible to use BRYNOVIN?
BRYNOVIN is recommended for adults with type 2 diabetes who may struggle with pill forms and is not intended for people with type 1 diabetes.
What makes BRYNOVIN unique compared to other diabetes medications?
BRYNOVIN is the first oral liquid formulation of sitagliptin, providing an alternative for patients who have difficulty swallowing pills or prefer liquid medications.
How is BRYNOVIN administered?
BRYNOVIN is taken as a once-daily dose of 100 mg (4 mL) in conjunction with diet and exercise.
What is the mission of Azurity Pharmaceuticals?
Azurity Pharmaceuticals aims to deliver innovative, high-quality medicines that cater specifically to overlooked patient populations worldwide.
